Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Sando Pharma | Med Parmasi Group | Vit Georgia Parmi | Pip Company | Medimex |
|---|---|---|---|---|---|
| Total Revenue | 4,272 | 1,824 | 1,804 | 1,452 | 1,299 |
| Total COGS | -3,798 | -1,180 | -1,145 | -787 | -719 |
| Gross Profit | 473 | 644 | 660 | 665 | 580 |
| Gross Margin | 11.1% | 35.3% | 36.6% | 45.8% | 44.7% |
| Total Operating Expenses | -461 | -318 | -748 | -528 | -110 |
| EBITDA | 12 | 326 | -88 | 137 | 470 |
| EBITDA Margin | 0.3% | 17.8% | -4.9% | 9.4% | 36.2% |
| Total D&A | -9 | -27 | -21 | -2 | -21 |
| EBIT / Operating Income | 3 | 298 | -109 | 134 | 450 |
| Total Interest Expense | -11 | -29 | -92 | — | -0 |
| Profit Before Tax | -8 | 269 | -201 | 111 | 9,023 |
| Total Income Tax | 0 | -40 | 0 | -1 | 0 |
| Net Profit / (Loss) | -8 | 229 | -222 | 110 | 8,771 |
| Net Margin | -0.2% | 12.5% | -12.3% | 7.5% | 675.1% |
| Total Other Income | — | — | — | -24 | 8,040 |
| Total Interest Income | — | — | — | — | 534 |
| Company | Sector | EBITDA margin · FY 2018 | Percentile | Sector n |
|---|---|---|---|---|
| Medimex | Pharma | 36.2% | 88th pct | 86 |
| Med Parmasi Group | Pharma | 17.8% | 64th pct | 86 |
| Pip Company | Pharma | 9.4% | 47th pct | 86 |
| Sando Pharma | Pharma | 0.3% | 21st pct | 86 |
| Vit Georgia Parmi | Pharma | -4.9% | 13th pct | 86 |
Percentile is within each company's own sector across the whole FY2018 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.